Matthew L Hemming

8PUBLICATIONS
40CO-AUTHORS
Solid tumoursMolecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Apr 24, 2024
ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs.

Ewa Sicinska, Vijaya S R Kola, Joseph A Kerfoot

|Sep 29, 2022
Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST.

Inga-Marie Schaefer, Matthew L Hemming, Meijun Z Lundberg

|May 02, 2022
MOZ and Menin-MLL Complexes Are Complementary Regulators of Chromatin Association and Transcriptional Output in Gastrointestinal Stromal Tumor.

Matthew L Hemming, Morgan R Benson, Michael A Loycano

|Mar 24, 2022
Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression.

Matthew L Hemming, Patrick Bhola, Michael A Loycano

|Mar 06, 2021
Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients-A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN).

Bernd Kasper, Annie Achee, Kathrin Schuster

|Feb 13, 2021
Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate.

Kenji Iida, Amr H Abdelhamid Ahmed, Akiko Kawano Nagatsuma

Pageof 2

Frequent Collaborators

4 joint publications

George D Demetri

3 joint publications

Madeleine L Taddei

2 joint publications

Chandrajit P Raut

2 joint publications

Sandro Santagata